This study is looking at camizestrant, a new medicine, to see if it helps people with a certain type of early breast cancer called ER+/HER2-. This type of breast cancer has specific markers: it uses estrogen to grow (ER+) and doesn't have too much of a protein called HER2 (HER2-). The study compares camizestrant to regular hormone treatments given after surgery to stop cancer from coming back. People in this study have a higher risk of their cancer returning.

Key Points:

• Study Length: The treatment will last for 7 years, and patients will be followed for 10 years.
• Eligibility: Participants must be 18 or older, have had surgery for their cancer, and meet certain health criteria.
• Participation: Patients should not have severe diseases, another cancer, or be pregnant.

Participants might receive additional medicine called abemaciclib. The study aims to see how long patients stay cancer-free, how safe the treatment is, and overall survival rates. If you join, you'll need to visit the study site regularly and follow certain rules. This study could help find better ways to treat breast cancer in the future.